{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:03:04Z","timestamp":1790863384863,"version":"4.1.0"},"reference-count":26,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,9,21]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune-checkpoint inhibitors (ICIs) plus chemotherapy have demonstrated survival benefits in extensive-stage small cell lung cancer (SCLC). The integration of immunotherapy with concurrent chemoradiotherapy (CCRT) may improve survival outcomes in limited-stage SCLC (LS-SCLC). This phase II randomized controlled study was designed to evaluate the efficacy and safety of toripalimab consolidation versus observation in patients with LS-SCLC after CCRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted this phase II, randomized controlled trial in patients with LS-SCLC who had completed CCRT. Eligible patients were randomized 1:1 to either toripalimab consolidation (240\u2009mg every 3 weeks for up to 6 months) or observation. Randomization was stratified according to disease stage (I or II vs III) and the receipt of prophylactic cranial irradiation (PCI) (yes vs no). The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS), objective response rate and toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between June 30, 2020, and May 31, 2024, a total of 98 patients were randomized to receive either toripalimab consolidation (n=49) or observation (n=49) after CCRT. The trial was prematurely terminated on May 31, 2024. Objective responses were observed in 14 of 23 patients (60.9%) in the toripalimab group and in 9 of 24 patients (37.5%) in the observation group. The median PFS was not reached in the toripalimab group, compared with 14.1 months (95%\u2009CI 2.8 to 25.4) in the observation group (HR, 0.55; 95%\u2009CI 0.31 to 0.96). The median OS was not reached with toripalimab, compared with 30.3 months (95%\u2009CI 20.4 to 40.2) with observation (HR, 0.39; 95%\u2009CI 0.19 to 0.80). Treatment-related toxicities were generally mild. Adverse events led to discontinuation of study drug in 6 of 48 patients (12.5%) in the toripalimab group. Grade 3 pneumonitis or radiation pneumonitis occurred in two patient (4.2%) in the toripalimab group and one patient (2.0%) in the observation group. No grade 4 or 5 adverse events occurred in either group. Subgroup analyses of PFS and OS favored toripalimab over observation across all predefined subgroups, including age, sex, Eastern Cooperative Oncology Group performance status, smoking status, disease stage, response to CCRT and the receipt of PCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Consolidative toripalimab showed promising signals of improved PFS and OS with a manageable safety profile in patients with LS-SCLC. These findings warrant confirmation in larger, adequately powered randomized trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-016467","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:34:26Z","timestamp":1790861666000},"page":"e016467","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study (GASTO-1052A)"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04418648","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1771-2991","authenticated-orcid":false,"given":"Pengxin","family":"Zhang","sequence":"first","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China"},{"name":"Guizhou Provincial People\u2019s Hospital, Guiyang, Guizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DaQuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhuo","family":"He","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HongMei","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Air Force Hospital of Southern Theater Command of PLA, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Gansu Provincial Cancer Hospital, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Situ","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MengRu","family":"Wang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShiHong","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Gansu Provincial Cancer Hospital, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qiu","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1789-5088","authenticated-orcid":false,"given":"Yan","family":"Huang","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3335-3756","authenticated-orcid":false,"given":"Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026100106150874000_14.10.e016467.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.4859"},{"key":"2026100106150874000_14.10.e016467.2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29098"},{"key":"2026100106150874000_14.10.e016467.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.207"},{"key":"2026100106150874000_14.10.e016467.4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0058"},{"key":"2026100106150874000_14.10.e016467.5","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1200\/JCO.22.01359","article-title":"High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)\/RTOG 0538","volume":"41","author":"Bogart","year":"2023","journal-title":"JCO"},{"key":"2026100106150874000_14.10.e016467.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30318-2"},{"key":"2026100106150874000_14.10.e016467.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"2026100106150874000_14.10.e016467.8","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"The Lancet"},{"key":"2026100106150874000_14.10.e016467.9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/jamaoncol.2024.5019","article-title":"Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial","volume":"11","author":"Cheng","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026100106150874000_14.10.e016467.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404873"},{"key":"2026100106150874000_14.10.e016467.11","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO-25-01569","article-title":"Chemoradiation \u00b1 Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology\/Alliance LU005","volume":"44","author":"Higgins","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026100106150874000_14.10.e016467.12","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388"},{"key":"2026100106150874000_14.10.e016467.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.05.003"},{"key":"2026100106150874000_14.10.e016467.14","doi-asserted-by":"crossref","unstructured":"Jennison C , Turnbull BW . Group sequential methods with applications to clinical trials. 1st edn. New York: hapman and Hall\/CRC, 1999. Available: https:\/\/doi.org\/10.1201\/9780367805326","DOI":"10.1201\/9780367805326"},{"key":"2026100106150874000_14.10.e016467.15","unstructured":"Proschan M , Lan K , Wittes J . Statistical Monitoring of Clinical Trials: A Unified Approach. 2006. Available: http:\/\/link.springer.com\/10.1007\/978-0-387-44970-8"},{"key":"2026100106150874000_14.10.e016467.16","unstructured":"R Core Team . R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2025."},{"key":"2026100106150874000_14.10.e016467.17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO-25-02726","article-title":"Timing Is of the Essence: Sequencing Immune Checkpoint Blockade and Radiotherapy for Success in Lung Cancer","volume":"44","author":"Keane","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026100106150874000_14.10.e016467.18","doi-asserted-by":"crossref","first-page":"S1267","DOI":"10.1016\/j.annonc.2024.08.2324","article-title":"LBA81 Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the Adriatic trial","volume":"35","author":"Senan","year":"2024","journal-title":"Annals of Oncology"},{"key":"2026100106150874000_14.10.e016467.19","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/d41586-024-02789-5","article-title":"Skull bones harbour immune cells that are poised to target brain tumours","volume":"633","author":"Lee","year":"2024","journal-title":"Nature"},{"key":"2026100106150874000_14.10.e016467.20","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41577-025-01175-0","article-title":"Redefining CNS immune privilege","volume":"25","author":"Smyth","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"2026100106150874000_14.10.e016467.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30065-1"},{"key":"2026100106150874000_14.10.e016467.22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00517","article-title":"Ionizing Radiation-Induced Immune and Inflammatory Reactions in the Brain","volume":"8","author":"Lumniczky","year":"2017","journal-title":"Front Immunol"},{"key":"2026100106150874000_14.10.e016467.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101435"},{"key":"2026100106150874000_14.10.e016467.24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s43018-021-00180-1","article-title":"Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy","volume":"2","author":"Han","year":"2021","journal-title":"Nat Cancer"},{"key":"2026100106150874000_14.10.e016467.25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1258"},{"key":"2026100106150874000_14.10.e016467.26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1187"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-016467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:34:29Z","timestamp":1790861669000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-016467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,1]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/jitc-2026-016467"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-016467","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}